FDA Panel To Find If Regeneron Gout Drug's Risks Too High
An arthritis advisory committee is gathering to provide recommendations to the FDA regarding the use of the drug Arcalyst to treat gout flares. Arcalyst is already approved to treat two rare genetic disorders, familial cold auto-inflammatory syndrome and cryopyrin-associated periodic syndromes, or CAPS.
In background information released...
Already a subscriber? Click here to login